Zoliflodacin: First New Antibiotic Class for Gonorrhea in Decades Gets FDA Approval

Why Is a New Gonorrhea Antibiotic Urgently Needed?

Neisseria gonorrhoeae infects an estimated 82 million people annually worldwide, making it the second most common bacterial sexually transmitted infection. The bacterium has progressively developed resistance to every antibiotic class used to treat it — sulfonamides, penicillins, tetracyclines, fluoroquinolones, and now increasingly cephalosporins. Current treatment guidelines recommend injectable ceftriaxone 500 mg as first-line therapy, but resistance to ceftriaxone has been documented in multiple countries, including parts of East Asia, the UK, and Australia.

The WHO included N. gonorrhoeae on its priority list of antibiotic-resistant bacteria requiring urgent new treatments. Without new antibiotics, public health experts warn that gonorrhea could become increasingly difficult to treat, leading to increased complications including pelvic inflammatory disease, infertility, ectopic pregnancy, and enhanced HIV transmission. Zoliflodacin represents the first new mechanism of action against gonorrhea since the introduction of cephalosporins in the 1980s.

How Does Zoliflodacin Work Against Resistant Gonorrhea?

Zoliflodacin belongs to the spiropyrimidinetrione class and works by inhibiting the type II topoisomerase (DNA gyrase) of N. gonorrhoeae at a binding site distinct from fluoroquinolones. This novel mechanism means that existing fluoroquinolone resistance mutations do not confer cross-resistance to zoliflodacin. In vitro studies have demonstrated activity against clinical isolates, including those resistant to ceftriaxone, azithromycin, and ciprofloxacin.

The Phase 3 trial enrolled approximately 930 patients with uncomplicated urogenital, rectal, or pharyngeal gonorrhea across multiple countries. A single oral dose of zoliflodacin 3g achieved a microbiological cure rate of approximately 96% for urogenital infections, with somewhat lower rates for rectal and pharyngeal infections — meeting non-inferiority criteria compared to ceftriaxone 500 mg injection. The oral administration is a significant practical advantage, eliminating the need for injection and enabling treatment in resource-limited settings. The most common side effects were mild gastrointestinal symptoms, primarily nausea and diarrhea, which generally resolved quickly.